{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-21-007467","form_type":"8-K","ticker":"SLSN","cik":"0000883107","company_name":"SOLESENCE, INC.","filed_at":"2021-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:04:15.977408+00:00","generated_at":"2026-06-28T14:44:58.057329+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Nanophase Q3 revenue $7.9M up 80% YoY; nine-month net income $2.7M","bullets":["Q3 revenue $7.9M vs $3.9M YoY; nine-month revenue $22.1M vs $12.3M.","Nine-month net income $2.7M ($0.04 EPS gain) vs $0.8M in 2020.","Solésence beauty science nine-month revenue $13.4M, up 204% YoY, exceeding full-year 2020.","Personal Care Ingredients revenue $5.3M (+28%); Advanced Materials $3.4M (-8%).","Purchase orders in hand for $27M+; ~$10M applies to 2021 orders."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-21-007467","json":"https://secwatch.observer/filing/0001171843-21-007467.json","markdown":"https://secwatch.observer/filing/0001171843-21-007467.md","text":"https://secwatch.observer/filing/0001171843-21-007467.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/883107/000117184321007467/0001171843-21-007467-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/883107/000117184321007467/f8k_110321.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T14:44:58.057329+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}